Survivin and Cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes

Histology and Histopathology

Volumn 22, Issue 1-3, 2007, Pages 61-77

  Mori, F ^a   Piro, F R ^b   Della Rocca, C ^c   Mesiti, G ^a   Giampaoli, S ^a   Silvestre, G ^d   Lazzaro, Domenico ^a,e  

^a Merck Research Laboratories   (Italy)

^b SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e IRBM   (Italy)

Author keywords

1,2 dimethylhydrazine; Colon cancer; Mouse

Indexed keywords

1,2 DIMETHYLHYDRAZINE; BETA CATENIN; CYCLOOXYGENASE 2; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CELL LEVEL; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; DYSPLASIA; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECTUM CANCER; TUMOR DIFFERENTIATION;

1,2-DIMETHYLHYDRAZINE; ANIMALS; BETA CATENIN; CELL DIFFERENTIATION; COLON; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; TISSUE DISTRIBUTION;

EID: 33846392922     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Abrams J. (2002). Competition and compensation: coupled to death in development and cancer. Cell 110, 403-406.
2. Adida C., Crotty P., McGrath J., Berrebi D., Diebold J. and Altieri D. (1998). Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol. 152, 43-49.
3. Aizu W., Guda K., Nambiar P., Xin T., Thibodeau M., Rosenberg D. and Giardina C. (2003). p53 and its co-activator p300 are inversely regulated in the mouse colon in response to carcinogen. Toxicol. Lett. 144, 213-224.
4. Altieri D. (2003). Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3, 46-54.
5. Altznauer F., Martinelli S., Yousefi S., Thurig C., Schmid I., Conway E., Schoni M., Vogt P., Mueller C., Fey M., Zangemeister-Wittke U. and Simon H. (2004). Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J. Exp. Med. 199, 1343-1354.
6. Ambrosini G., Adida C. and Altieri D. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921.
7. Araki Y., Okamura S., Hussain S., Nagashima M., He P., Shiseki, M., Miura K. and Harris C. (2003). Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 63, 728-34.
8. Bach S., Renehan A. and Potten C. (2000). Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis 21, 469-76.
9. Berger B., Vucson B, and Diteberg J. (2003). Gene mutations in advanced colonic polyps: potential marker selection for stool-based mutated human DNA assays for colon cancer screening. Clin. Colorectal Cancer 3, 180-185.
10. Bernstein C., Bernstein H., Payne C.M., Gareval H. and anonymous (2000). Field defects in progression to adenocarcinoma of the colon and esophagus. Electronic J. 3, 167-183.
11. Boivin G., Washington K., Yang K., Ward J., Pretlow T., Russell R., Besselsen D., Godfrey V., Doetschman T., Dove W., Pitot H., Halberg R., Itzkowitz S., Groden J. and Coffey R. (2003). Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124, 762-777.
12. Bolton M., Lan W., Powers S., McCleland M., Kuang J. and Stukenberg P. (2002). Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol. Biol Cell. 13, 3064-77.
13. Brittan M. and Wright N. (2002). Gastrointestinal stem cells. J. Pathol. 197, 492-509.
14. Chen J., Jin S., Tahir S., Zhang H., Liu X., Sarthy A., McGonigal T., Liu Z., Rosenberg S. and Ng S. (2003). Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J. Biol. Chem. 278, 486-490.
15. Clevers H. (2004). Wnt breakers in colon cancer. Cancer Cell 5, 5-6.
16. Cohn S., Schloemann S., Tessner T., Seibert K. and Stenson W. (1997). Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Invest. 99, 1367-1379.
17. Corpet D. and Pierre F. (2003). Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol. Biomarkers Prev. 12, 391-400.
18. Crook N., Clem R. and Miller L. (1993). An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 67, 2168-2174.
19. de Santa Barbara P., van den Brink G. and Roberts D. (2003). Development and differentiation of the intestinal epithelium. Cell Mol. Life Sci. 60, 1322-1332.
20. Dong M., Guda K., Nambiar P., Rezaie A., Belinsky G., Lambeau G., Giardina C. and Rosenberg D. (2003) Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 24, 307-315.
21. Eberhart C., Coffey R., Radhika A., Giardiello F., Ferrenbach S. and DuBois R. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188.
22. el-Deiry W., Tokino T., Velculescu V., Levy D., Parsons R., Trent J., Lin D., Mercer W., Kinzler K. and Vogelstein B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
23. Elder D., Baker J., Banu N., Moorghen M. and Paraskeva C. (2002). Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J. Pathol. 198, 428-434.
24. Fortugno P., Wall N., Giodini A., O'Connor D., Plescia J., Padgett K., Tognin S., Marchisio P. and Altieri D. (2002). Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell Sci. 115, 575.
25. Gianani R., Jarboe E., Orlicky D., Frost M., Bobak J., Lehner R. and Shroyer K. (2001). Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum. Pathol. 32, 119-125.
26. Guda K., Upender M., Belinsky G., Flynn C., Nakanishi M., Marino J., Ried T. and Rosenberg D. (2004). Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability. Oncogene 23, 3813-3821.
27. Gupta R. and Dubois R. (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1, 11-21.
28. Hanahan D. and Weinberg R. (2000). The hallmarks of cancer. Cell 100, 57-70.
29. Hao X., Tomlinson I., Ilyas M., Palazzo J. and Talbot I. (1997). Reciprocity between membranous and nuclear expression of beta-catenin in colorectal tumours. Virchows Arch. 431, 167-172.
30. Hata K., Yamada Y., Kuno T., Hirose Y., Hara A., Qiang S. and Mori H. (2004). Tumor formation is correlated with expression of beta-catenin-accumulated crypts in azoxymethane-induced color carcinogenesis in mice. Cancer Sci. 95, 316-320.
31. Heidebrecht H., Buck F., Endl E., Kruse M., Adam-Klages S., Anderser K., Frahm S., Schulte C., Wacke, H. and Parwaresch R. (2001). Ki-Mcm6, a new monoclonal antibody specific to Mcm6: comparison of the distribution profile of Mcm6 and the Ki-67 antigen. Lab. Invest 81, 1163-1165.
32. Hoffman W., Biade S., Zilfou J., Chen J. and Murphy M. (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277, 3247-3257.
33. Hur K., Kim J., Yoon B., Lee J., Choi J., Oh G. and Kim D. (2000), Overexpression of cyclin D1 and cyclin E in 1,2-dimethylhydrazine dihydrochloride-induced rat colon carcinogenesis. J. Vet. Sci. 1, 121-126.
34. Iurlaro M., Demontis F., Corada M., Zanetta L., Drake C., Gariboldi M.. Peiro S., Cano A., Navarro P., Cattelino A., Tognin S., Marchisio P. and Dejana E. (2004). VE-cadherin expression and clustering maintain low levels of survivin in endothelial cells. Am. J. Pathol. 165, 181-189.
35. Johnstone R., Ruefli A. and Lowe S. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164.
36. Karam S. (1999). Lineage commitment and maturation of epithelial cells in the gut. Front Biosci. 4, D286-D298.
37. Kawasaki H., Altieri D., Lu C., Toyoda M., Tenjo T. and Tanigawa N. (1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58, 5071-5074.
38. Kearsey S. and Labib K. (1998). MCM proteins: evolution, properties, and role in DNA replication. Biochim. Biophys. Acta. 1398, 113-136.
39. Khare S., Cerda S., Wali R., von Lintig F., Tretiakova M., Joseph, L., Stoiber D., Cohen G., Nimmagadda K., Hart J., Sitrin M., Boss G. and Bissonnette M. (2003). Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res. 63, 3517-23.
40. Kim P., Plescia J., Clevers H., Fearon E. and Altieri D. (2003). Survivin and molecular pathogenesis of colorectal cancer. Lancet 362, 205-209.
41. Kinzler K. and Vogelstein B. (1997). Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761-763.
42. Knosel T., Yu Y., Stein U., Schwabe H., Schluns K., Schlag P.M., Dietel M. and Petersen I. (2004). Overexpression of cyclooxygenase-2 correlates with chromosomal gain at the cyclooxygenase-2 locus and decreased patient survival in advanced colorectal carcinomas. Dis. Colon Rectum 47, 70-77.
43. Korinek V., Barker N., Morin P., van Wichen D., de Weger R., Kinzler K., Vogelstein B. and Clevers H. (1997). Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275, 1784-1787.
44. Kotsinas A., Evangelou K., Zacharatos P., Kittas C. and Gorgoulis V. (2002). Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators. Am. J. Pathol. 161, 1619-1634.
45. Kozoni V., Tsioulias G., Shiff S. and Rigas B. (2000). The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen. Carcinogenesis 21, 999-1005
46. Krysan K., Merchant F., Zhu, L., Dohadwala, M., Luo, J., Lin, Y., Heuze-Vourc'h, N., PÃμld, M., Seligson, D., Chia, D., Goodglick, L., Wang, H., Strieter R., Sharma S. and Dubinett S. (2004) COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18, 206-208.
47. Labib K., Tercero J. and Diffley J. (2000). Uninterrupted MCM2-7 function required for DNA replication fork progression. Science 288, 1643-1647.
48. Lazzaro D., Price M., de Felice M. and Di Lauro R. (1991). The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 113, 1093-1094.
49. Li F. and Altieri D. (1999). Transcriptional analysis of human survivin gene expression. Biochem. J. 344 Pt 2, 305-311.
50. Mahotka C., Liebmann J., Wenzel M., Suschek C., Schmitt M., Gabbert H. and Gerharz C. (2002). Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 9, 1334-1342.
51. Maihöfner C., Charalambous M.P., Bhambra U., Lightfoot T., Geisslinger G., Gooderham N.J. and anonymous (2003) Expression of cyclooxygenase-2 parallels expression of interleukin-1 beta, interleukin-6 and NF-kappaB in human colorectal cancer. Cancer Biol. 24, 665-671.
52. Masferrer J., Koki A. and Seibert K. (1999). COX-2 inhibitors. A new class of antiangiogenic agents. Ann. NY Acad. Sci. 889, 84-86.
53. Morin P., Sparks A., Korinek V., Barker N., Clevers H., Vogelstein B. and Kinzler K. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275, 1787-1190.
54. Nambiar P., Giardina C., Guda K., Aizu W., Raja R. and Rosenberg D. (2002). Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res. 62, 3667-3374.
55. Nambiar P., Girnun G., Lillo N., Guda K., Whiteley H. and Rosenberg D. (2003) Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int. J. Oncol. 22, 145-150.
56. Nishihara H., Kizaka-Kondoh S., Insel P. and Eckmann L. (2003). Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc. Natl. Acad. Sci. USA 100, 8921-8926.
57. O'Driscoll L., Linehan R. and Clynes M. (2003). Survivin: role in normal cells and in pathological conditions. Curr. Cancer Drug Targets 3, 131-152.
58. Ohmori T., Asahi S., Sato C., Maki F., Masumoto A. and Okada K. (1999). Bcl-2 protein expression and gut neurohormonal polypeptide/amine production in colorectal carcinomas and tumor-neighboring mucosa, which closely correlate to the occurrence of tumor. Histol. Histopathol. 14, 37-44.
59. Padmanabhan V., Callas P., Philips G., Trainer T. and Beatty B. (2004). DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J. Clin. Pathol. 57, 1057-1062.
60. Papanikolaou A., Wang Q., Papanikolaou D., Whiteley H. and Rosenberg D. (2000). Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21, 1567-1572.
61. Potten C., Li Y., O'Connor P. and Winton D. (1992). A possible explanation for the differential cancer incidence in the intestine, based on distribution of the cytotoxic effects of carcinogens in the murine large bowel. Carcinogenesis 13, 2305-2312.
62. Prescott S. and Fitzpatrick F. (2000). Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta 1470, M69-78.
63. Sarela A., Macadam R., Farmery S., Markham A. and Guillou P. (2000). Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46, 645-650.
64. Sellin J., Umar S., Xiao J. and Morris A. (2001). Increased beta-catenin expression and nuclear translocation accompany cellular hyperproliferation in vivo. Cancer Res. 61, 2899-906.
65. Semple J. and Duncker B. (2004). ORC-associated replication factors as biomarkers for cancer. Biotechnol. Adv. 22, 621-31.
66. Shao J., Sheng H., Aramandla R., Pereira M., Lubet R., Hawk E., Grogan L., Kirsch I., Washington M., Beauchamp R. and DuBois R. (1999). Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 20, 185-191.
67. Sheng H., Shao J., Williams C., Pereira M., Taketo M., Oshima M., Reynolds A., Washington M., DuBois R. and Beauchamp R. (1998). Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis 19, 543-549.
68. Shiff S. and Rigas B. (1997). Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113, 1992-1998.
69. Shpitz B., Bomstein Y., Mekori Y., Cohen R., Kaufman Z., Grankin M. and Bernheim J. (1997). Proliferating cell nuclear antigen as a marker of cell kinetics in aberrant crypt foci, hyperplastic polyps, adenomas, and adenocarcinomas of the human colon. Am. J. Surg. 174, 425-430.
70. Stewart D. and Nelson W. (1997). Identification of four distinct pools of catenins in mammalian cells and transformation-dependent changes in catenin distributions among these pools. J. Biol. Chem. 272, 29652-29662.
71. Takahashi M., Mutoh M., Kawamori T., Sugimura T. and Wakabayashi K. (2000) Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 21, 1319-1327.
72. Tamm I., Wang Y., Sausville E., Scudiero D., Vigna N., Oltersdorf T. and Reed J. (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-20.
73. Thompson C. (1995). Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462.
74. Vaux D., Haecker G. and Strasser A. (1994). An evolutionary perspective on apoptosis. Cell 76, 777-779.
75. Wali R., Khare S., Tretiakova M., Cohen G., Nguyen L., Hart J., Wang J., Wen M., Ramaswamy A., Joseph L., Sitrin M., Brasitus T. and Bissonnette M. (2002). Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol. Biomarkers Prev. 11, 1653-1662.
76. Yu J., Leung W., Ebert M., Ng E., Go M., Wang H., Chung S., Malfertheiner P. and Sung J. (2002). Increased expression of survivin in gastric cancer patients and in first degree relatives. Br. J. Cancer 87, 91-97.
77. Zhang, T., Otevrel, T., Gao, Z., Gao, Z., Ehrlich, S., Fields, J. and Boman B. (2001). Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 61, 8664-8667.